Wire · opportunities
Real-World Data Reinforce Liso-Cel Efficacy in R/R MCL
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Real-world data for lisocabtagene maraleucel (liso-cel) in relapsed/refractory mantle cell lymphoma (MCL) show an 89% overall response rate and safety outcomes consistent with the pivotal TRANSCEND clinical trial. The therapy is approved in the US since May 2024 and Europe since November 2025, providing effective treatment particularly in BTK inhibitor-refractory MCL with limited options.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new proven option with liso-cel showing strong real-world efficacy and manageable toxicity in aggressive MCL cases resistant to existing BTK inhibitors. Prioritise integrating this CAR T therapy as your frontline salvage approach to capture unmet patient needs.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics